Skip to main content

Dermatologic Disease

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

PEEL Therapeutics
PEEL TherapeuticsUT - Salt Lake City
1 program
Addressing Inequity in DermatologyN/A1 trial
Active Trials
NCT06056648RecruitingEst. Apr 2026
Incyte
IncyteDE - Wilmington
1 program
Vitiligo Registry for Adults and Children in the UKN/A1 trial
Active Trials
NCT06218082Not Yet Recruiting30Est. Feb 2030

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
IncyteVitiligo Registry for Adults and Children in the UK
PEEL TherapeuticsAddressing Inequity in Dermatology

Clinical Trials (2)

Total enrollment: 30 patients across 2 trials

NCT06218082IncyteVitiligo Registry for Adults and Children in the UK

Vitiligo Registry for Adults and Children in the UK

Start: May 2026Est. completion: Feb 203030 patients
N/ANot Yet Recruiting
NCT06056648PEEL TherapeuticsAddressing Inequity in Dermatology

Addressing Inequity in Dermatology

Start: Aug 2023Est. completion: Apr 2026
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 30 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.